2025 Oncology Institute
April 19, 2025 | 8:05 PM EST
- Home
- Clinical Resources Search
- PQI in Action: Ripretinib (Qinlock®) for Treatment of Adults with Advanced Gastrointestinal Stromal Tumors
Ripretinib (Qinlock®) for Treatment of Adults with Advanced Gastrointestinal Stromal Tumors
Download PQI pdf 1.03MB
Last Updated: December 1, 2023
By: New York Oncology Hematology, NY | Oregon Health & Science University Knight Cancer Institute, OR | Oncology Consultants, TX
About this PQI in Action
In an effort to promote higher quality patient care, NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow-up to the Ripretinib (QINLOCK®) for Treatment of Adults with Advanced Gastrointestinal Stromal Tumors PQI and explores how the medically integrated teams at Oncology Consultants, Oregon Health & Science University, and New York Oncology and Hematology incorporate the information found in the PQIs as part of their daily workflow. This article will discuss how utilizing the Ripretinib (QINLOCK®) for Treatment of Adults with Advanced Gastrointestinal Stromal Tumors PQI elevates patient care.
More About This PQI in Action
Find a PQIPQI
PQI: Ripretinib (Qinlock®) for Treatment of Adults with Advanced Gastrointestinal Stromal Tumors
Last Updated: February 2, 2024